XBI241004P93000
- 0.11
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
Capital Markets' Top 30 Global Ideas for the Fourth Quarter
AbbVie Withdraws Exviera From EU Market for Commercial Reasons
Incyte Analyst Ratings
Optimism Around Aquestive As It Moves Forward With Severe Allergy, Baldness Candidate
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today
'Buy This; Sell That' Within Each Sector – Oppenheimer
Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades'
Reported Earlier, Alnylam's Vutrisiran Data Highlights Early Impact on Key Cardiac Biomarkers, Alnylam Eyes First-Line Therapy for ATTR Amyloidosis
Stocks With the Highest Consensus of Expected ROE Growth, Goldman Sachs Says
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
(ABBV) - Analyzing AbbVie's Short Interest
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Biotech IPOs Return as Sector Recovers After Funding Overhang
Cassava Sciences Stock Sinks 14% After $40 Million Settlement With SEC
CNBC Halftime Report Final Trades: Meta Platforms, Accenture, AbbVie, The Walt Disney Company
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Healthcare Venture Investors Ante Up. Public Markets Remain Cool. -- Barrons.com
Exact Sciences, Quanterix Extend Slide After Medicare Rates